PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
PDS Biotechnology Corporation (Nasdaq: PDSB) has rescheduled its 2021 fourth quarter and full-year earnings release and conference call to March 31, 2022, at 8:00 AM EDT. The delay is attributed to the need for additional time to complete its audit and file the Annual Report on Form 10-K for the fiscal year ending December 31, 2021. The conference call will review financial results and provide a business update. Investors can access the call via a live webcast on PDS Biotech’s website.
- Scheduled earnings call and financial results review indicates ongoing business operations and transparency.
- Delay in releasing financial results raises concerns about the company's audit processes.
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from Wednesday, March 23, 2022 to 8:00 AM EDT on Thursday, March 31, 2022 as PDS Biotech needs additional time to complete its audit and file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Following the release, management will host a conference call to review the financial results and provide a business update.
Thursday, March 31, 2022, 8:00 AM Eastern Daylight Time
Domestic: 877-407-3088
International: 201-389-0927
Webcast: PDS Biotechnology Earnings Webcast
A live webcast of the conference call will also be available on the investor relations page of the Company's website at www.pdsbiotech.com. After the live webcast, the event will be archived on PDS Biotech’s website for six months.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.
Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital
FAQ
When is PDS Biotechnology's next earnings release?
Why was the earnings call for PDS Biotechnology rescheduled?
How can I listen to the PDS Biotechnology earnings conference call?
What will PDS Biotechnology discuss during the earnings call?
